Skip to main content
. 2022 Jan 25;100(7):781–787. doi: 10.1111/aos.15097

Fig. 2.

Fig. 2

Time to immunomodifying treatment. (A) Time to treatment with methotrexate. HR = 0.34, 95% CI: 0.22–0.52, p = 1.04 × 10−6. (B) Time to treatment with anti‐TNF‐α therapy. HR = 0.10, 95% CI: 0.05–0.20, p = 1.98 × 10−10. Analysis is adjusted for age of uveitis, uveitis diagnosis before arthritis onset and gender. The dotted line represents the median survival. CI = confidence interval; HR, hazard ratio.